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Abstract
Bupropion is an antidepressant with excellent tolerability and fe to side f!ffects or drug
interactions. These characteristics suite it ioellfo r use both in the elderly and in the medically ill.
Huwever, early reports ofseirures with bupropion therapy in patients with bulimia limited its use.
The pharmacology, tdJicacy, toxicity, and side dftct profile qfboth the immediate release (IR) and
the recently available sustained release(SR)jOrmulations ofbupropion are reviewed. Bupropion S R
is associated with a reduced seizure incidence (0. /%) compared to that finmd with the IR
formulation (0.4%). Recent reports, however, demonstrate that the half-lif« qf bupropion is
prolonged in the elderly and that the elderly accumulate bupropion metabolites. Potential toxic
effects, including seizures and psychosis, may result from high bupropion plasma levels and the
accumulation ofbupropion metabolites in the elderly or in those with impaired renal or liver
function. Clinical reports in the elderlydemonstrate that lower (75-225 mgjday) doses ofbupropion
are assuciatedioithfe ioersidedftcts and equal efficacy to thatfou nd with higher duses. Bupropion is
a good antidepressant choicejOr the elderly and the medically ill, provided additional precautions,
including the use ofloio doses, are taken. Bupropionshould either be avoided orbe usedwith extreme
caution in anyone who is at increased risk ofseizuresor who has a history qf'psychosis oran eating
disorder.
(Suggested Keywords, Ind ex Medi cus MeSH : Bupropion, Geriatric Psychiatry,Psycho-
ses, S ubstance-I nduced, Seizures, Depression, Pharmacokinetics, Antidepressiue Agents, Psychoge-
riatrics, Psychopharmacology)
INTRODUCTION
Depression is a common psychi atric problem in th e e lde rly, a lt hough th e exac t
pr eva len ce is uncertain. The Nationa l Institute of Mental Health (NIMH) Epidemio-
logica l Catchment Ar ea (ECA) progr am round a pr eval en ce rat e or 2.5% for all
affec t ive di sorders in people aged 65 yea rs a nd olde r ( I) . However, depression ca n be
diffi cult to recogn ize a nd may manifest diITerently in olde r adults . T hus, the ECA rat e
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may be an underestimate (2) . Blaz er (3) an alyz ed th e ECA dat a a nd found th a t
depressive sym ptoms were reported in 27% of those ag ed 60 yea rs or olde r. This high
pr eval en ce of depressive symptoms in th e elde rly, togethe r with this segme nt of th e
population increasin g fast er th an a ny ot her, indi cates th e need for an tid epressa nt
th e rapy th at is highl y effec t ive, well tolerat ed , a nd rela t ively free of side e ffec ts and
drug interacti on s.
Bupropion (BUP) , on e of th e " second ge ne ra t ion" a nt idepressa n ts, was origi-
nally introduced in 1985. The uni cyclic aminoketone is a unique a n tidepr essan t in
structure, (4) is well tolerated , a nd has few side e ffec ts (5) or drug interact ions (6) ;
th ese cha ra cte rist ics suite it particul arly well lor use both in th e elde rly a nd in th e
medica lly ill. In March 1986, however, bupropion immed ia te release (IR) was
withdrawn from th e market after reports indi cat ed an increased rate of se izures in
bulimic patients (7) . In May 1989, bupropion IR was re-int roduced with a reduced
maximum dosage recommendation intended to decreas e th e incid en ce of seizures. In
lat e 1996, th e Food and Drug Administration (FDA) approved a sus ta ined- release
(SR) form of bupropion , whi ch is rep orted to furth er reduce conce rns abou t se izures.
However, toxic effects in add ition to se izure s have been no ted wit h bupropi on,
including th e exace rba t ion or ini tiation of psych oti c sym ptoms.
PHARMACOLOGY
Bupropion weakly blocks dopamine uptak e (8) . This is not beli eved to ade q ua te ly
account for it s antidepressant act ivity, however, a nd a norad ren ergic mecha nism has
a lso been sugges ted (8) . Oral adm inist ra t ion of bupropion result s in ra pid absorpt ion,
a nd bupropion undergoes exte nsive fir st pass met ab ol ism (9) . The met aboli sm of
bupropi on results in th e formation of three major met ab oli tes: hyd roxybupropion
(HB) , threoh ydrobupropion (TB) , and eryth rohydrobupro pion (EB) (9) . Leizu re ( 10)
found th e half lives of BUP, TB , EB, a nd HB to be 9.8, 19.8, 26.8 , a nd 22.2 hou rs,
resp ectively. In 1995, however, Sweet ( 11) found th e half lives for BUP , TB , EB, and
HB to be increased in th e elde rly a t 32.4, 38.8, 6 1.4, a nd 34.2 hours, respectively.
Furthermore, th e elde rly accumulate a n inordinat e a mo unt of bupropion met ab olites
( I I) . Met ab oli sm of bupropi on SR results in th e sa me break down product s as does
met abolism of th e IR form. Future study, however, will be necessary to lea rn mo re
a bout th e ph armacokinetic properti es of bupropion SR a nd how th ese com pa re to I he
IR form . Excr etion of'bupropion occurs through th e urine (87%) a nd feces ( 10%), with
onl y 0.5% excreted un ch an ged (9) . Decr eases in liver fun ction , an d pr esumab ly
kidney fun cti on , impair e limina t ion, result in incr eased blood levels of bupro pion a nd
its met ab olites, a nd incr eas e th e cha nce of toxicity ( 12).
EFFICACY
Kane, (13) in a study of 38 depressed patients 55 years or older, foun d no
differen ce in effi cacy between th ose randomly designated to receive eithe r a mean
bupropion dose of 323 mgld ay (high dose) or a mean of 150 mg/day (low dose).
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Lik ewise, Branconnier, (14) in a study of 63 depressed pa ti ents 55 years or olde r,
found no significa nt differen ces in efficacy bet ween th ose ran domly designated to
receive bupropion a t eithe r 450 rug/day (high dose) or 150 rng/day (low dose).
However, h igh dose bupropion dem on strated fast er onse t of action and gr eat er
a nxiolyt ic acti vity th an low dose bupropi on . Pr eskorn ( 15) found a curvilinea r
relation ship between a nt ide pressant efficacy a nd bupropion trou gh plasma conce ntra-
tion , with efficacy decr eased with eithe r ve ry high or very low trou gh plasma level s.
Likewise, Go lden ( 16) found poor efficacy to be associa ted wit h high bupropion
met ab olite conce ntra t ions . Bupropion is not th e only a nti depressa nt in which reduced
doses in th e elde rly have been recommended. For example, J arvic ( 17) found that
doses as low as 25 mg and 50 mg/day of imipramine a rc effec tive in treating older
adults with depression .J a rvie ( 17) a lso not ed t hat further dosage increases were not
likely to be success ful but were likely to produce undesirable side effec ts .
SIDE EFFECTS
Overa ll, bupropion is well to lerat ed and exhibits few side effects (5). For
exa mple, Feighner (5) found no differen ce in treatment-em ergent adverse events
between bupropion a nd Iluoxet inc, on e of th e se lec t ive seroto nin rcuptakc inhibitors
(SSIUs). Agitation a nd excite me nt a re th e most com mon side effec ts associat ed with
th e discontinuat ion of bupropi on ( 18). Althou gh Prien ( 19) has suggest ed th at
bupropi on may be associa te d with a ntide pressant induced man ia less often than with
othe r a n tide pressan ts, ra re report s of bupropi on ind uced mania do exist. For ex-
ample, Bittman (20) rep ort s th e case of a 78 year old man ta king lith ium who became
grandiose a nd manic when bupropi on was sta rted. Bupropion demonstrat es lilli e to
no a nt icho line rg ic, a nt ihist im inic, or a nt iad re ne rg ic effect (2 1). There is no known
ca rd iotox icity a nd it does not ca use or thos ta t ic hypot en sion (22) . In fact, bupropion
has been found to be a useful age nt in treating pa ti ents with heart d isease (23,24). On
ave rage, bupropion ca uses only mild weight loss a nd mi ni mall y a ffects appetite (25).
Bupropion is th e on ly a nt ide pressan t reported to improve sex ua l function (26). Few
drug interactions have been not ed with bupropion , a nd inhibition of cytochrome P450
live r isocnzymes has not been reported (6). Thus, not only is bupropi on free of man y
of t he side effec ts of the older tri cyclic a nt ide pressants, but a lso it has th e following
advantages over t he newer se lec t ive se ro tonin rc-upta ke inhibitors : fewer sexual sid e
effec ts, fewer d rug in teract ions, and an absence of liver enzyme inhibition.
BUPROPION AND SEIZU RES
In 1989, David son , (27) in a review of over four th ou sand cases, concluded that
th e incid en ce of se izu res associa ted with bupropi on th erap y is appro ximate ly 0.4%;
thi s was deem ed to be e ithe r no different from or j us t slight ly high er than th e
incid en ce of se izures with th e use of othe r tri cyclic a nd tetracyclic a nti dep ressants. In
1993, a prosp ective study with ove r three th ou sand patien ts reproduced this sa me
0.4% se izu re incid en ce rat e with buprop ion th erapy (28) . Davidson (27) found that
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seve ral patien t cha rac te rist ics were associated with an incr eased risk of se izure wit h
bupropi on usage: pri or history of se izures, hist ory of orga nic brain disease, hist ory of
a n ea t ing disorder, doses gre a te r tha n 450 mg/day, rap id dose escala t ion, a nd hig h
plasm a levels of bupropi on or its metabolites. T o m inim ize th e risk of se izures, the
1998 Physicians Desk Referen ce (29) (PDR) recommen ds a n initi al bu pr op ion IR
dose of 100 mg twice a day for a mi nimum of three days before incr easing th e dose to
100 mg three ti mes a day. If in a few weeks respon se is not ade qua te th e dose can be
rai sed to a maximum 01' 450 mg/day (29).
Peak bupropi on plasm a levels are 50% lower with th e SR formulation tha n wit h
th e IR form (6). The risk of seizu res with bupropi on th erapy is cor re la ted with th e
peak plasm a level. Therefor e it is not surpris ing th at the incidence of se izu res wit h
th e SR formulation , with doses not exceed ing 300 mg/d ay, is lower (0. 1%) t han t ha t
found with th e IR form (0.4%) (30) . The efficacy a nd side effec t profil e of th e two
forms of bupropion arc ot herwise simila r (6). Th e PDR recommends begin ning
bupropion SR treatment a t 150 rug/day as a sing le dose (29). Th is ca n be increased to
150 mg twice a day, th e recommended target dose, as ea rly as day four (29). A
maximum dose of 200 mg twice a day is recommended (29) . However, given high
plasm a bupropi on levels and accu mula t ion of bupropion met ab olit es in th e elde rly,
eve n th e target dose of 300 mg/d ay of bupropi on SR may be excess ive when treat ing
geria tric depression.
BUPR OPION Al'IJD PSYCH OSIS
A review of th e lit eratu re uncovered seven cases of bupropion treatment
eme rge nt psych osis or deliriu m wit h psychoti c featu res (3 1-37) . Golden (3 1) re-
ported th at four out of 13 bupropion treat ed patient s developed psych otic symptoms,
on ly one of who had no history of psych osis. In two of the cases, psychot ic symptoms
a ppea re d to be dose-relat ed. Likewise, Goode (32) reported t hat three out of nine
patien ts diagnosed with schizoaffe ct ive disorder expe rie nced exace rba t ions of psy-
chot ic sympto ms when treat ed with bupropi on . Becker (33) rep ort ed tha t two ou t of
twelve patients, both of who had a previous d iagn osis of schizophre nia, expe rience d
abe rran t beli efs and visua l expe rience s with bupropi on treatm ent. Va n-Putt en (34)
report ed a case of ac ute delirium with psychotic featu res in a patient tr eated wit h
bupropion. Am es (35) report ed three cas es of bupropion induced psychosis, wit h
e me rge nt symptoms including delu sion s as well as auditory a nd visua l hallu cin ations.
A history of psychotic symptoms was present in two of th e three indi vidua ls.
Bupropion my pr ecipitat e psych osis by blocking dopamine upt ak e a nd ca using
dopaminergic overdrive (36). Lib erzon (36) rep ort ed a case of bupropi on trea tme nt
eme rge nt delirium with psych oti c features in a patient who had a hist ory of psych osis
a nd was taking th e dopamine ago nist a manta d ine. Go etz (37) reported th e onse t or
worsening of hallucination s or confusion with buprop ion treatment in th ree pati ents
with Parkinson s disease who were receiving a dopa mine ago nis t, eit he r amantadine
or levodopa. Fr om thi s review, bup ropi on induced psych osis a ppears to be more likely
to occur in patients with ce r ta in risk factors. Vulnerab le pa ti ent s include th ose tak ing
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dopaminergic medi cations or th ose with a history of psychosis (3 1- 37) .Johnston (38)
recomm ends that , in patients with a history of psychosis, bupropi on not be used as
first line t rea t ment.
Thes e reports contrast with th e less than 4% rat e of treatm ent emerge nt
psychotic symptoms reported in a total of2,398 patients who received bupropion up to
1985 (38) . Thus, th e incid en ce of treatment e me rge nt psych osis with bu propion,
wh en individual pa ti ent cha rac te rist ics are di sr egarded , a ppears to be no gre a ter
th an th at seen with othe r antidepressants (38). However, th e pr ecedi ng da ta suggest
th at bupropion is ca pa ble of inducing or exace rba t ing psych oti c sym ptoms, particu-
larly in th e pr esen ce of cer ta in vulnerabilities.
DISC USSION
The elde rly may be more vu lnerable to bupropion induced psychosis and othe r
tox ic effec ts than youn ger ad ult s with depression. A possible mech anism for increased
risk of bupropion tox icity in th e elde rly is th at th ey have high peak plasm a bupropion
levels a nd acc umula te bupropion metabolites ( I I) . The elde rly a re a lso more like ly
th an younge r adults to hav e impairments of liver or kidney funct ion, both ofwhich are
expected to result in eleva ted bupropi on and bupropi on meta bolite leve ls ( 12).
U ntowa rd drug int eracti ons a re an othe r possibl e expla na t ion for bu propion indu ced
toxic effec ts, a lt ho ug h drug interacti ons have been rep orted ra rely wit h bupropion
(39) . Onset or wor sening or psych osis a nd confus ion has been associat ed with
concom ita n t adm inist ra t ion or bupropion with th e dopamine ago nists levodopa (37)
and amantadine (36) , findings whi ch support the dopaminergic ove rd rive hypothesis.
Lithium (35) and sel ective serotonin reuptake inhibitors (34) have likewise been
associat ed with th e onse t or worsening of delirium or psychosis wh en combined with
bupropion.
In conclusion, bupropion possesses man y cha racteris t ics th at off er adva ntages
over othe r a n t ide pressa nts in th e t reatment or dep ression both in t he elde rly a nd in
th e medi call y ill; th ese include excelle n t tolerability, few side effec ts (5), and an
a bse nce or P450 liver enzyme inhibition or drug int eracti on s (6) . However, pot ential
toxi c effects, particularly seizures a nd psychosis, may result from high bupropion
plasma level s and from th e accumulation of bupropi on met ab olit es in the elde rly or in
those with impaired renal or liver function ( 12). Pat ients receiving dopaminergic
med ications are also at increased risk of developing psychotic sympto ms when given
bupropion (36,37). Thus, low doses (75-225 mg/day) of bupropion a re recommended
in th e elde rly, th ose with liver or renal dysfuncti on , a nd in th ose a lrea dy ta king
dopamine agonists. In add it ion, bupropion sho uld either be avo ided or used with
ex t re me ca ut ion in a nyone who is a t incr eased risk or seizures or who has a hist ory or
psych osis or an eat ing disorder. Also, bupropion sho uld not be combined with other
medi cation s known to lower th e seizure thresh old . Future work es ta blish ing a
th erapeutic plasm a level range Ior bupropion in th e elde rly would faci lita te th e sa fe
a nd effec t ive use or thi s unique a nt ide pressan t.
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